

# TAKAFULINK DANA ESG GLOBAL

All information as at 31 July 2024 unless otherwise stated


Semua maklumat adalah seperti pada 31 Julai 2024 melainkan jika dinyatakan

## Objective / Objektif Dana

Takafulink Dana ESG Global (The Fund) aims to maximise returns over long term by investing in a qualified Sustainable and Responsible Investment (SRI) Fund.

Takafulink Dana ESG Global (Dana) bertujuan memaksimumkan pulangan jangka masa panjang dengan melabur dalam Dana Pelaburan Mampan dan Bertanggungjawab (SRI) yang layak.

## Where the Fund invests Komposisi Pelaburan Dana



## Asset Allocation Peruntukan Aset

	% NAV
1 Nomura Global Shariah Sustainable Equity Fund	98.93
2 Cash, Deposits & Others	1.07

## Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan Prudential BSN Takaful Berhad

Inception Date / Tarikh Diterbitkan 20/03/2023


Current Fund Size / Saiz Dana Terkini RM4,386,617.26

Annual Fund Management Charge / Caj Pengurusan Dana Tahunan 1.50% per annum

Current NAV / NAB Terkini RM1.31613

## How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana  
Takafulink Dana ESG Global Vs. Dow Jones Islamic Market  
Market Developed Markets Index



## Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	-2.36%	4.81%	11.62%	21.68%	NA	NA	31.61%
Benchmark / Penanda Aras	-2.17%	4.99%	9.79%	21.06%	NA	NA	35.85%
Outperformance / Perbezaan Prestasi	-0.19%	-0.18%	1.83%	0.62%	NA	NA	-4.24%

Source / Sumber: Lipper for Investment Management and Bloomberg, 31 July 2024

# TAKAFULINK DANA ESG GLOBAL

All information as at 31 July 2024 unless otherwise stated

Semua maklumat adalah seperti pada 31 Julai 2024 melainkan jika dinyatakan

## Monthly Update / Laporan Bulanan Terkini

### Fund Review & Strategy

The Fund returned -2.36% for the month, underperforming the benchmark return of -2.17% by 0.19%. Year-to-date, The Fund returned 17.96%, outperforming the benchmark return of 14.30% by 3.66%. Global developed equity market was undergoing healthy correction since mid-July where YTD outperformers observed the largest drawdown especially in semiconductor space. Throughout the period, the Target Fund Manager observed market rotation to small cap and value names where low-quality companies outperformed. Closer to the end of July, positive sentiment recovered as triggered by mega cap tech companies' comments on continuous AI investments and the headline news on reversal of China chip curb. They would be slightly more cautious about trading the market going forward by monitoring the economy development closely and focus on investing selectively. By region, positive contribution to the relative performance from NA was not enough to offset EU where selection was a drag. By sector, Consumer Discretionary and IT were the main detractors partially offset by selection in Industrials. The top contributors to the relative performance were Pentair and Thermo Fisher Scientific. Despite weaker market demand, Pentair delivered strong profit margin improvement in their Q2 earnings where 80/20 transformation plan contributes. After multiple quarters of downward revision concerns, Thermo Fisher Scientific reported earnings beats and guidance raise ease market concern that the destocking phase since end of pandemic has bottomed. On the other hand, the bottom contributors to the relative performance were Novo Nordisk and ASML. Novo Nordisk received multiple overhangs from biotech companies such as Roche, and Viking pharmaceuticals where they reported robust data on their GLP-1 drugs on early phases. The Target Fund Manager believe that Cagrisema data release at end of 2024 would be a positive catalyst for Novo Nordisk to remove the overhangs. While ASML misses EUV order expectations and suffered from the negative AI sentiment, they continue to believe that ASML would benefit from its leadership lithography technology as a monopoly in the space and have taken advantage on the pullback.

### Tinjauan & Strategi Dana

Dana mencatat pulangan -2.36% pada bulan ini, tidak mengatasi pulangan penanda -2.17% dengan perbezaan 0.19%. Sejak awal tahun sehingga bulan tinjauan, Dana memperoleh pulangan 17.96%, mengatasi pulangan penanda aras 14.30% dengan perbezaan 3.66%. Pasaran ekuiti maju global sedang melalui proses pembetulan yang sihat sejak pertengahan Julai di mana yang berprestasi tinggi sejak awal tahun telah merosot terutamanya dalam ruang semikonduktor. Sepanjang tempoh tersebut, Pengurus Dana Sasaran memerhatikan pasaran berputar kepada saham permodalan kecil dan syarikat berkualiti rendah yang mengatasi prestasi. Menjelang akhir Julai, sentimen positif pulih apabila dicetus oleh ulasan syarikat teknologi permodalan besar mengenai pelaburan AI yang berterusan dan berita utama mengenai pembalikan sekatan cip China. Pengurus Dana Sasaran akan lebih berhati-hati mengenai perdagangan pasaran pada masa hadapan dengan memantau perkembangan ekonomi secara teliti dan fokus terhadap pelaburan secara terpilih. Mengikut rantau, sumbangan positif kepada prestasi relatif daripada Amerika Utara tidak memadai untuk mengimbangi EU di mana pemilihan telah meleret. Mengikut sektor, Pengguna Bukan Keperluan dan Teknologi Maklumat merupakan penjejas utama namun sebahagiannya diimbangi oleh pemilihan dalam Perindustrian. Penyumbang utama kepada prestasi relatif ialah Pentair dan Thermo Fisher Scientific. Walaupun permintaan pasaran lebih lemah, Pentair memberikan peningkatan margin keuntungan yang kukuh dalam pendapatan Q2 yang mana pelan transformasi 80/20 membuahkan hasil. Selepas diselubungi kebimbangan semakin menurun sejak beberapa suku tahun yang lalu, Thermo Fisher Scientific melaporkan rentak pendapatan dan panduan mengurangkan kebimbangan pasaran bahawa fasa penyahstokan sejak akhir pandemik telah berakhir. Sebaliknya, penyumbang terendah kepada prestasi relatif ialah Novo Nordisk dan ASML. Novo Nordisk menerima pelbagai 'overhang' daripada syarikat bioteknologi seperti Roche, dan farmaseutikal Viking yang mana syarikat tersebut melaporkan data yang kukuh ke atas ubat GLP-1 pada fasa awal. Pengurus Dana Sasaran percaya bahawa pelaporan data Cagrisema pada penghujung 2024 akan menjadi pemangkin positif buat Novo Nordisk untuk melenyapkan 'overhang'. Walaupun ASML tidak memenuhi jangkaan pesanan EUV dan dibebani sentimen AI yang negatif, Pengurus Dana Sasaran terus percaya bahawa ASML akan mendapat manfaat daripada kedudukannya dalam teknologi litografi sebagai monopoli dalam ruang tersebut dan telah mengambil kesempatan daripada penarikan semula.

Source / Sumber: Fund Commentary, July 2024, Nomura Asset Management Malaysia Sdn. Bhd.

### Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL